Evaluation of Potential Allergenicity of New Wheat Varieties
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Know the risks and potential benefits of clinical studies and talk to your health care provider before participating.
Read our disclaimer for details.
The goal of the study is to determine accurate blood test levels that can predict whether or not subjects are truly allergic to certain foods. In this study, subjects that are clinically documented to be wheat-allergic will participate in a double blind oral food challenge. Blood will be collected from the subject to evaluate the potential allergenicity of proteins introduced into genetically modified crops and evaluate wheat-specific IgE antibody reactivity to biotech and conventional wheat varieties.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
1 Year to 21 Years (Child, Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Pediatric and adult subjects between the ages of 1 (inclusive) to 21 years (inclusive) that have sensitivity to wheat
Age 1 year to 21 years of any sex and any race
Physician-diagnosed food allergy to wheat with convincing clinical history of food allergy to wheat AND a skin prick test positive to wheat (diameter of wheal 3 mm or greater than negative control) or a detectable serum food-specific IgE level (ImmunoCAP > 0.35 kUA/L) to wheat within the previous 12 months or at the time of entry into the study
If no history of clinical reactivity to wheat, then a positive skin prick test to wheat (diameter of wheal 3 mm or greater than negative control) OR a detectable serum food-specific IgE level to wheat within the previous 12 months or at the time of entry into the study
Patients who meet any of the following criteria are eligible for enrollment as study participants if they meet all other criteria, but will not undergo a DBPCFC: A) Recent (within one year) failed open OFC B) Positive DBPCFC to wheat at CHCO C) Recent (within one year) exposure to wheat resulting in immediate IgE-mediated allergic symptoms (within 2 hours of ingestion; symptoms such as urticaria, angioedema, congestion, rhinorrhea, wheezing, respiratory compromise, hypoxia, hypotension)
Written informed consent from parent/guardian and assent (when age appropriate).
Willingness to submit specimen for laboratory serum IgE testing
Willingness to submit lab specimen for ELISA testing
Inability to discontinue antihistamines for skin prick testing and OFCs
FEV1 value <80% predicted OR any clinical features of moderate or severe persistent asthma, as defined by the 2007 NHLBI guidelines table for classifying asthma, at the time of entry into the study
Use of >500 μg/day fluticasone or equivalent
Asthma requiring either:
> 1 hospitalization in the past year for asthma or > 1 ER visit in the past 6 months for asthma
Use of steroid medications (IV, IM or oral) for asthma in the following manners:
history of daily oral steroid dosing for >1 month during the past year or
steroid course/burst in the past 3 months (except for steroid dosing used in the treatment of an allergic reaction during the DBPCFC) or
>2 steroid courses/bursts in the past year
History of intubation due to allergies or asthma
Diagnosis of active eosinophilic gastrointestinal disease in the past year
Severe atopic dermatitis, as assessed by a Three-Item Severity Score of 6 or greater